As of 10:30 AM on the 3rd, Seegene is trading at 176,900 KRW, up 2.43% from the previous day. The trading volume is 195,123 shares, which is about 41.24% of the previous day's volume. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.


On February 3rd, Kim Seunghoe, a researcher at DS Investment & Securities, stated, "Although the stock price is sluggish due to concerns about a performance peak-out, 1) the increase in the number of testing institutions using AllplexTM due to the global expansion of equipment distribution and 2) ongoing demand from countries worldwide for accurate diagnosis of variant viruses suggest that performance growth is possible in 2021. In 2022, with cash holdings exceeding 1 trillion KRW, the possibilities of 1) entering new businesses and M&A and 2) strengthened shareholder return policies are expected to act as factors that will increase corporate value in the future." He set Seegene's target price at 254,000 KRW.


Over the past five days, individual investors have net sold 91,054 shares of Seegene, while foreigners and institutions have net bought 58,045 shares and 29,018 shares, respectively.



※ Source: AI Investment Assistant AI Rassiro


※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing